Oncolytics Biotech (ONCY) Income Statement (2025 - 2026)
Income Statement report data from Mar 31, 2025 to Mar 31, 2026 for Oncolytics Biotech (ONCY).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Mar 31, 2025 | |
|---|---|---|
Operating Expenses | ||
Research And Development | 4.55M (+62.50%) | 2.80M |
Selling General And Administrative | 4.73M (+113.06%) | 2.22M |
Operating Expenses | 9.28M (+84.86%) | 5.02M |
Depreciation And Amortization | 20K (0.00%) | 20K |
Operating Income | ||
Operating Income | -9.28M (+84.86%) | -5.02M |
Ebit | -9.28M (+84.86%) | -5.02M |
EBITDA | -9.26M (+85.20%) | -5.00M |
Other Income / Expenses | ||
Interest Income | 40K (-66.67%) | 120K |
Net Interest Income | 40K (-66.67%) | 120K |
Other Non Operating Income | 40K (-87.10%) | 310K |
Net Income | ||
Net Income From Continuing Operations | -9.24M (+96.18%) | -4.71M |
Net Income | -9.24M (+96.18%) | -4.71M |
Comprehensive Income Net Of Tax | -9.24M (+100.87%) | -4.60M |